Warum die Pathophysiologie des Morbus Gaucher bei der Entstehung von Krebserkrankungen eine Rolle spielt
von Marie Henning und Ali Canbay, Medizinische Klinik des
Universitätsklinikums Knappschaftskrankenhaus Bochum
erschienen im go-schee brief Ausgabe 34/2020
Literatur
Aerts JM, Hollak CE, Boot RG, Groener JE, Maas M. Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):449-56. doi: 10.1007/s10545-006-0272-5. PMID: 16763917.
Baris HN, Cohen IJ, Mistry PK. Gaucher disease: The metabolic defect, pathophysiology, phenotypes and natural history. Pediatr Endocrinol Rev Per 2014;12 (Suppl. 1):72–81.
Boven LA, van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM, Laman JD. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 2004;122:359-69. doi: 10.1309/BG5V-A8JR-DQH1-M7HN.
Chifman J, Laubenbacher R, Torti SV. A systems biology approach to iron metabolism. Adv Exp Med Biol 2014;844:201-25. doi: 10.1007/978-1-4939-2095-2_10.
de Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, Haussinger D, Hollak CE. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 2006;36:53-58.
Kumar V, Abbas A, Fausto N, Aster J. Robbins and Cotran: Pathologic Basis of Disease. 8th ed. Saunders / Elsevier 2009. eBook ISBN: 9781437721829.
Lefebvre T, Reihani N, Daher R, de Villemeur TB, Belmatoug N, Rose C, Colin-Aronovicz Y, Puy H, Le Van Kim C, Franco M, Karim Z. Involvement of hepcidin in iron metabolism dysregulation in Gaucher disease. Haematologica 2018;103:587-596. doi: 10.3324/haematol.2017.177816. Epub 2018 Jan 5.
Lorenz F, Pawłowicz E, Klimkowska M, Beshara S, Bulanda Brustad A, Skotnicki AB, Wahlin A, Machaczka M. Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1. Blood Cells Mol Dis 2018;68:35-42. doi: 10.1016/j.bcmd.2016.10.010. Epub 2016 Oct 20.
Maffettone C, Chen G, Drozdov I, Ouzounis C, Pantopoulos K. Tumorigenic properties of iron regulatory protein 2 (IRP2) mediated by its specific 73-amino acids insert. PLoS One 2010 Apr 13;5(4):e10163. doi: 10.1371/journal.pone.0010163.
Mistry PK, Taddei T, vom Dahl S, Rosenbloom BE. Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. Crit Rev Oncog 2013;18:235-246. doi: 10.1615/critrevoncog.2013006145.
Petsko GA, Grabowski GA, Kolodny EH. Gaucher disease. In: Scriver CM, Beudet AL, Sly WS, Valle D, editors. Molecular Bases of Inherited disease. McGraw Hill; 2010
Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E. Gaucher disease and cancer incidence: A study from the Gaucher Registry. Blood 2005;105:4569-4572.
Shen Y, Li X, Dong D, Zhang B, Xue Y, Shang P. Transferrin receptor 1 in cancer: a new sight for cancer therapy. Am J Cancer Res 2018;8:916-931.
Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Levade T, Astudillo L, Serratrice J, Brassier A, Rose C, Billette de Villemeur T, Berger MG. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mol Sci 2017:18:441. doi: 10.3390/ijms18020441.
Wątek M, Piktel E, Wollny T, Durnaś B, Fiedoruk K, Lech-Marańda E, Bucki R. Defective Sphingolipids Metabolism and Tumor Associated Macrophages as the Possible Links Between Gaucher Disease and Blood Cancer Development. Int J Mol Sci. 2019 Feb 15;20(4):843. doi: 10.3390/ijms20040843.